Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Debanjana Chatterjee
JONE
Debanjana Chatterjee
JonesTrading
Wall Street Analyst
★★☆☆☆
#2209
on 13Foresight · ranked by our own returns
57%
Success Rate
+7.1%
Average Return
17 of 30 calls profitable · -3.8% vs benchmark
📈 Across the calls we could measure, roughly 57% of Debanjana Chatterjee's ratings turned a profit when each position was held for 1 year — averaging +7.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

144 Buy 12 Hold 0 Sell
Debanjana's Stock Coverage 19 ratings · 2026-07-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ATHE
Alterity Therapeutics
 Jul 08, 2026 BUY Buy
+74.7% avg upside
6 analysts
$16.00
186.74% Upside
 ·
IRD
Opus Genetics
 Jul 08, 2026 BUY Strong Buy
+160.2% avg upside
24 analysts
$10.00
143.95% Upside
 -2.3%
EYPT
EyePoint Pharmaceuticals
 Jul 06, 2026 BUY Strong Buy
+127.7% avg upside
19 analysts
$43.00
206.94% Upside
 -2.9%
SGMT
Sagimet Biosciences, Inc. Class A
 Jul 01, 2026 BUY Strong Buy
+283.5% avg upside
15 analysts
$31.00
316.58% Upside
 ·
TBPH
Theravance Biopharma
 Jun 29, 2026 HOLD Hold
+8.6% avg upside
18 analysts
$17.00
0.00% Downside
 -0.3%
ABCL
AbCellera Biologics
 Jun 25, 2026 BUY Strong Buy
+80.5% avg upside
15 analysts
$13.00
83.11% Upside
 -7.1%
SION
Sionna Therapeutics, Inc.
 Jun 25, 2026 BUY Strong Buy
+21.1% avg upside
11 analysts
$63.00
43.22% Upside
 +2.9%
ABSI
AbSci
 Jun 24, 2026 BUY Strong Buy
+6.2% avg upside
18 analysts
$13.00
17.05% Upside
 +6.7%
SYRE
Spyre Therapeutics
 Jun 16, 2026 BUY Strong Buy
-21.7% avg upside
23 analysts
$104.00
9.08% Upside
 +17.4%
PHVS
Pharvaris
 Jun 11, 2026 BUY Strong Buy
+26.0% avg upside
14 analysts
$52.00
44.76% Upside
 +13.3%
CLSDQ
Clearside Biomedical
 May 29, 2026 HOLD Hold
+11086.5% avg upside
10 analysts
 — -10.9%
NTLA
Intellia Therapeutics
 May 27, 2026 BUY Strong Buy
+153.1% avg upside
37 analysts
$29.00
72.22% Upside
 +25.9%
ARMP
Armata Pharmaceuticals
 May 27, 2026 BUY Strong Buy
+180.1% avg upside
4 analysts
$20.00
292.11% Upside
 -10.6%
OPTEY
Opthea Limited Sponsored ADR
 May 22, 2026 HOLD Hold
+30596.9% avg upside
7 analysts
 — ·
TVRD
Tvardi Therapeutics
 May 12, 2026 BUY Strong Buy
+351.3% avg upside
23 analysts
$12.00
140.06% Upside
 +22.9%
EVAX
Evaxion Biotech
 May 08, 2026 BUY Strong Buy
+291.1% avg upside
6 analysts
$10.00
207.72% Upside
 -4.2%
CTNM
Contineum Therapeutics, Inc. Class A
 May 08, 2026 BUY Strong Buy
+31.6% avg upside
8 analysts
$26.00
66.09% Upside
 +6.9%
TRVI
Trevi Therapeutics
 May 06, 2026 BUY Strong Buy
+9.5% avg upside
16 analysts
$24.00
29.06% Upside
 +32.2%
HYFT
MindWalk Holdings
 Apr 15, 2026 BUY Strong Buy
+198.4% avg upside
3 analysts
$5.00
247.30% Upside
 -7.0%
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Debanjana Chatterjee — Frequently Asked Questions
How accurate are Debanjana Chatterjee's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Debanjana's ratings were profitable over a one-year hold, with an average return of +7.1% per rating, or -3.8% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Debanjana ranked on 13Foresight?
Debanjana Chatterjee is currently ranked #2209 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Debanjana cover?
Debanjana most recently has ratings on ATHE, IRD, EYPT, SGMT, TBPH, ABCL, SION, ABSI, SYRE, PHVS, CLSDQ, NTLA and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.